Text Size

2010 Catalyst Meeting: Leading Experts Discuss New Directions in Glaucoma Research

Nick Marsh-Armstrong, PhD and Martin Wax, MD at the 2010 Catalyst Meeting
Nick Marsh-Armstrong, PhD and Martin Wax, MD at the 2010 Catalyst Meeting

The Glaucoma Research Foundation Catalyst Meeting took place at the Mandarin Oriental Hotel in San Francisco from September 9 to 11, 2010 in San Francisco.

Eighteen leading scientists and physicians from around the world met to discuss retinal ganglion cell degeneration in glaucoma

The group addressed three aspects of nerve degeneration: the genetics, the sequence of events, and markers of progression. For each aspect they considered what we know, what we need to know, and what tools and models we need to achieve our research goals.

Many participants recommended pursuing new models of glaucoma for the purpose of understanding the sequence of events. Another reason for defining the earliest events was the opportunity for a rescue strategy.

Functional imaging was recommended as an important technique for validating the sequence of events, the progression of vision loss, and the impact of potential therapeutic interventions.

There was a strong sense among attending scientists and physicians that these efforts will result in identifying new physiologic or molecular biomarkers that will be useful in the diagnosis and management of glaucoma.

New Directions in Collaborative Research

Following the Catalyst Meeting, the Glaucoma Research Foundation Science Committee began the process of choosing a team of investigators for a new collaborative research program.

The new team will build on the research of the Catalyst For a Cure with a focus on identifying new, sensitive and specific, clinically applicable markers for disease detection, progression, and therapeutic intervention.

Last reviewed on February 14, 2014

This article appeared in the January 2011 issue of Gleams.


Was this helpful? Yes No